Episode Details

There are two kinds of clinicians—the ones who follow algorithms, and the ones who understand the “why.”

Be the second on Patreon:

👉 https://www.patreon.com/PearlsandPrep

🎙️ Episode Description

Antidepressants are foundational in psychiatry — and also one of the easiest ways to accidentally destabilize mood if bipolar risk isn’t recognized early. In this episode of Pearls and Prep, we break down the most important, high-yield pearls on SSRI activation, bipolar switching, and why not all antidepressants carry the same risk.

We review what activation really means, why venlafaxine (Effexor) consistently shows higher switch rates than SSRIs and bupropion, and how those risks change dramatically depending on whether a mood stabilizer is on board. You’ll hear the real numbers clinicians should know, including how antidepressant monotherapy nearly triples mania risk, while concurrent mood stabilizer use sharply reduces — and may even reverse — that risk over time.

We also cover Symbyax (olanzapine + fluoxetine) as a model for safe antidepressant use in bipolar depression, highlighting why pairing antidepressant effects with antimanic protection works — and what tradeoffs come with it. Throughout the episode, we emphasize practical screening pearls, red flags that should slow prescribing, and strategies that protect both patients and clinicians.

This is a must-listen episode for psych NPs, students, and prescribers who want to treat depression effectively without triggering mood instability.

27

Stocking Stuffer Bonus: High-Yield Pearls on Bipolar Activation, SSRIs, and Mood Stabilizers

Pearls and Prep

pearlsandprep@mail.com

https://patreon.com/PearlsandPrep?utm_medium=unknown&utm_source=join_link&utm_campaign=creatorshare_creator&utm_content=copyLink